LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Landon C BrownMatthew D TuckerRamy SedhomEric B SchwartzJason ZhuChester KaoMatthew Kyle LabriolaRajan T GuptaDaniele MarinYuan WuSantosh GuptaTian ZhangMichael R HarrisonDaniel J GeorgeAjjai AlvaEmmanuel S AntonarakisAndrew J ArmstrongPublished in: Journal for immunotherapy of cancer (2021)
This multicenter study shows significantly better outcomes with ICI therapy in patients harboring P/LP versus VUS LRP1B alterations, independently of TMB/MSI status. Further mechanistic and prospective validation studies are warranted.